NCT07473128 2026-03-16
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Pharmacosmos A/S
Phase 3 Not yet recruiting
Clinical Trials
6 trialsNCT07255612 2025-12-01
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06364904 2025-02-21
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT06714266 2024-12-03
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT06297811 2024-03-07
Myeloprotection With Trilaciclib in Pan-cancer Population
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05862610 2023-07-24
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting